Thermo Fisher Scientific Sees $4.3M Bearish Put Sweep as Stock Sits Near 52-Week Lows

May 26, 2026

By TrendSpider Editor

TMO market update based on latest unusual_options data.

Thermo Fisher Scientific Sees $4.3M Bearish Put Sweep as Stock Sits Near 52-Week Lows

Thermo Fisher Scientific (TMO) is drawing attention in the options market after a single unusually large put contract carried a premium of $4,302,870, signaling notable bearish conviction from a sophisticated trader. The stock is currently trading at $448.20, nearly flat on the session with a -0.01% price move, and remains well off its 52-week high of $643.99. With TMO hovering closer to its 52-week low of $385.46 than its peak, the bearish options flow adds a layer of concern to an already pressured name.

Key Drivers of the TMO Stock Move

Main Catalyst: A single put contract on TMO with a $470 strike expiring June 5, 2026, printed with a volume of 1,770 contracts and an open interest percentage change of 59,000%, representing $4,302,870 in total premium. The contract is currently in-the-money, meaning the market is already trading below the strike price, amplifying the bearish read on this flow.
Bull Case: TMO is trading at $448.20, which is above its 52-week low of $385.46, suggesting the stock has already absorbed significant downside pressure. A contrarian view could argue the in-the-money put represents a hedge on an existing long position rather than a directional short bet.
Bear Case: The open interest surge of 59,000% on this contract signals that this is almost entirely new positioning, not a roll of an existing trade. With the $470 strike sitting above the current price of $448.20 and expiration arriving on June 5, 2026, only ten days away, the trader is paying a significant premium for near-term downside protection or outright bearish exposure.

The forward setup for TMO carries real uncertainty. The stock has lost roughly 30% from its 52-week high of $643.99, and the appearance of a deep-premium, short-dated, in-the-money put suggests at least one institutional player is not expecting a near-term recovery. The tight expiration window of June 5, 2026, points to a trader with a specific near-term catalyst or downside target in mind, whether tied to macro conditions affecting life sciences spending, currency headwinds, or broader sector rotation out of healthcare tools names.

TMO Unusual Options Activity

One contract drove all of the unusual activity flagged in TMO today:

Type: Put | Strike: $470 | Expiry: June 5, 2026 | Volume: 1,770 | Open Interest Change: 59,000% (in-the-money)

This is the sole unusual contract flagged, with a total premium of $4,302,870 representing the entirety of notable options flow for TMO on the session. The in-the-money status of this put, combined with a near-zero prior open interest base implied by the 59,000% surge, indicates this is overwhelmingly fresh positioning rather than a hedge roll.

TMO Seasonality

Late May and early June have historically represented a transitional period for large-cap healthcare tools stocks, as the market digests Q1 earnings results and begins to price in midyear guidance revisions. A short-dated put expiring in early June fits a pattern of traders positioning around any potential mid-quarter updates or conference presentations.

TMO Relative Performance

TMO is essentially unchanged on the session at -0.01%, underperforming any names showing positive momentum in the broader market today. Trading at $448.20 against a 52-week range of $385.46 to $643.99, TMO sits in the lower third of its annual range, reflecting the broader pressure on life sciences and laboratory equipment companies that have faced sluggish biopharma spending and funding headwinds over the past year. The stock would need to recover more than 43% from current levels just to retest its 52-week high, a significant hurdle in the current environment.